Regenerative medicine

Our

Mission

Mogrify® has developed a proprietary direct cellular conversion technology that utilizes a systematic big-data approach (Rackham et al., Nature Genetics, 2016) developed over a 10-year period via a multi-national research collaboration. By deploying next-generation sequencing and gene regulatory network data, the platform enables the prediction of the transcription factors (or small molecules) required to produce any target cell type from any source cell type.

The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether affecting a direct transdifferentiation between a mature cell type to another mature cell type.

Mogrify is applying its proprietary and award-winning platform to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of ex vivo and in vivo cell therapies for indications of high unmet clinical need in hematological, immunological, ophthalmological and other disease areas.

Uniquely positioned to address a regenerative medicine market estimated to be $39 billion USD by 2023, Mogrify is commercializing its technology via licensing, product development, and drug development. Based in Cambridge, UK, the Company has raised over $20 million USD funding from Ahren Innovation Capital, Parkwalk, 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III.

Explore our science

Meet

Our Leadership Team

LEADERSHIP TEAM
BOARD OF DIRECTORS

Our

HISTORY

2009

FANTOM 5 LAUNCH

RIKEN scientists launch international consortium to provide insight into the regulatory landscape of the transcriptome across as many cell states as possible.

2014

MOGRIFY VALIDATION

Collaboration with Jose Polo to test cell conversions begins and three conversions are validated in just several months.

2016

NATURE GENETICS

Mogrify V1 platform and cell conversions results published in Nature Genetics journal featuring on the front page.

2018/2019

GROWTH PHASE

$3.7M seed capital raised, Dr. Darrin M. Disley, OBE appointed as CEO, and Dr. Jane Osbourn, OBE appointed as Chair, hired 40 scientists and raised an additional $16 million in the initial close of Series A funding.

2011

MOGRIFY DEVELOPMENT

Julian Gough and Owen Rackham begin the V1 platform development using the unpublished FANTOM 5 consortium data.

2015

FOUNDATION PATENT

Julian Gough, Owen Rackham, Jose Polo file a patent application for the V1 platform and over 30 direct cell conversions.

2016/2018

INCORPORATION

Mogrify is incorporated in February 2016 by the three academic Co-founders: J. Gough, O. Rackham & J. Polo with pre-seed and grant funding to begin the industrial development and application of the V1 platform.

2020

PROOF OF CONCEPT

First milestone & royalty-bearing deals executed. Appointed Dr. Lorenz Mayr to the Board of Directors and Scientific Advisory Board. Progression of internal programs to in vitro and in vivo proof-of-concept stage.

Our

Awards

Scrip-Awards-2019-Winner_Mogrify

MSD’s Innovation
Award 2019

The Innovation Award at Scrip recognizes the significant potential the Company’s direct cellular conversion technology has to disrupt the future development of new medicines.

BusinessWeekly-2019-Winner_Mogrify

Disruptive Technology Award 2019

The ‘Disruptive Technology’ category at the Business Weekly Awards, recognises the Company’s novel bioinformatic platform, which is built upon a decade of world-class multidisciplinary science.

LSX-Awards-2019-Winner_Mogrify

Seed Stage Finance Raise of the Year 2019

Lifestars is a celebration of the success stories, innovations, transformational deals and the people, teams and organizations that play such a critical role in the advancement of the industry.

CambridgeIndependant-Awards-2019-Winner_Mogrify

Named ‘The One to Watch’ 2019

Recognizing the potential of the Company’s proprietary direct cellular conversion technology, enabling any mature adult cell to be transformed into any other, without going through a pluripotent stem cell-state.